130 results on '"Valderrama, Begoña P."'
Search Results
2. Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study
3. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
4. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
5. Progress in systemic therapy for advanced-stage urothelial carcinoma
6. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
7. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
8. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
9. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial
10. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
11. Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis
12. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
13. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
14. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)
15. PD34-11 NIVOLUMAB PLUS GEMCITABINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA: RESULTS OF ANALYSES TO CHARACTERIZE BENEFIT IN RESPONDERS FROM THE PHASE 3 CHECKMATE 901 TRIAL
16. Current Therapy for Metastatic Urothelial Carcinoma
17. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy
18. Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
19. Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
20. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
21. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial
22. Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440]
23. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
24. Progress in systemic therapy for advanced-stage urothelial carcinoma
25. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
26. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
27. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
28. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
29. Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.
30. Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study.
31. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)
32. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
33. LBA02-08 RESULTS FROM THE EXTENDED FOLLOW-UP IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER IN THE CHeckMATE 274 TRIAL
34. Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary
35. French of the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
36. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
37. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
38. PD10-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL
39. PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
40. German translation of the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
41. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. Spanish translation
42. Portuguese Translation of: Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
43. Italian translation of the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
44. Arabic translation
45. Arabic translation of the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
46. French translation of: Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
47. Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma
48. MP41-12 AVELUMAB FIRST-LINE MAINTENANCE PLUS BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF TIME TO END OF NEXT-LINE THERAPY IN JAVELIN BLADDER 100
49. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma
50. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.